Novo Nordisk Shares Plunge 21% as Eli Lilly Gains Edge in GLP-1 Market

Key Facts

1Novo Nordisk (NVO) shares plunged 21% following disappointing clinical study results.

2Eli Lilly's Zepbound and oral orforglipron outperformed Novo Nordisk's key GLP-1 drugs in head-to-head obesity and diabetes studies.

Novo Nordisk (NVO) shares plummeted 21% following the release of disappointing clinical trial data for its key treatments. The sell-off was triggered by head-to-head studies showing that Eli Lilly’s (LLY) competing drugs outperformed Novo’s market-leading GLP-1 portfolio. Specifically, Eli Lilly’s Zepbound and its experimental oral drug orforglipron demonstrated superior efficacy in treating obesity and diabetes. This significant clinical setback poses a direct threat to Novo Nordisk's long-standing dominance in the high-growth weight-loss medication sector. Market analysts suggest that these results could signal a major shift in leadership within the pharmaceutical industry toward Eli Lilly. The 21% drop underscores the high stakes and intense competition currently defining the global metabolic health market.